Zydus Group’s Sentynl Therapeutics gains full control of Menkes Disease candidate CUTX-101

Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company under Zydus Lifesciences, Ltd., has finalized an agreement with Cyprium Therapeutics, Inc., a subsidiary of Fortress Biotech, Inc. ... Read More